Search results
Dec 5, 2023 · John Crowley with his daughter, Megan. The year is 1998 and Crowley and his wife just received crushing news. Their 15-month-old daughter, Megan, had just been diagnosed with a little-known genetic neuromuscular disease – Pompe disease – that meant her heart was failing rapidly. She’d be given only six months to live.
Nov 10, 2023 · The end of the quarter saw another step in John Crowley’s journey to develop medicines for Pompe disease with the FDA approval of Amicus Therapeutics’ Pombiliti + Opfolda as a second enzyme ...
John F. Crowley is our Chairman and CEO. John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start ...
Mar 1, 2017 · Crowley, 20-year-old sophomore at the University of Notre Dame, and her father, John, had met with Trump earlier in the day to discuss treatments for rare diseases like Pompe disease. Crowley was ...
Mar 1, 2017 · During his address to Congress last night, President Donald Trump introduced Megan Crowley, a 20-year-old woman with a rare disease. Crowley, who has a neuromuscular disorder known as Pompe ...
Summary. Extraordinary Measures, based on events in the life of John Crowley and his family, dramatizes the father's quest to find a cure for Pompe disease, a relatively rare genetic condition that afflicts two of his three children. The quest brings into play three powerful, often competing human motives: a father's love for his children, a ...
Sep 21, 2023 · The real John Crowley’s endeavors have led to significant advancements in Pompe treatment, giving hope to many suffering from the condition, and ultimately saving his children’s lives. Currently, he serves as the executive chairman and founding CEO of Amicus Therapeutics, a global biotechnology company dedicated to advancing therapies for a range of rare and devastating diseases.
